Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fas (CD95, APO-1) receptor is a transmembrane death receptor belonging to the TNF receptor superfamily, expressed on granulosa cells in ovarian follicles. Engagement of Fas by its ligand, FasL, leads to the induction of apoptosis via the caspase-8 pathway, playing a crucial role in the regulation of follicular atresia in the ovary. The signaling pathway is modulated by cytokines (e.g., interferon-γ), and cross-talks with other cellular pathways (e.g., ceramide-mediated signaling). Dysregulation of the Fas signaling pathway is implicated in several diseases, including cancer and reproductive disorders, and components of this pathway are being investigated as therapeutic targets and biomarkers.
Agonists induce apoptosis by triggering Fas-mediated cell death via caspase activation. Drugs may stabilize or enhance Fas/FasL interaction, or modulate downstream signaling (e.g., ceramide production)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fas (CD95) receptor (Fas (also known as CD95 or APO-1)).